Good to see traction in sales, particularly for the Athlete Movement Index product.
If it really gains traction in the US, this will be really significant for DVL.
The Medtronic opportunity could be the icing on top though, very significant longer term.
Still not sure why someone doesn’t take us out for $15m.
